Business & Tech Local Experts Question WHO Study That Called Into Question the Effectiveness Of Remdesivir for COVID Patients The results of a study released Friday prior to being peer-reviewed are alarming some Bay Area infectious disease specialists because they may mislead other doctors or the public.
Business & Tech Results of First Federal Double-Blind Study of Remdesivir In COVID-19 Patients Shows Quicker Recoveries The results of a federal study of the use of remdesivir to treat severely ill COVID-19 patients were announced Wednesday, and shares of Bay Area-based Gilead Sciences were trending up as a result — as was the rest of the stock market.
Business & Tech Inundated With Requests For Experimental Coronavirus Drug, Gilead Halts Individual-Case Program As predicted several weeks ago, Bay Area-based Gilead is at the center of the international conversation — and domestic desperation — about potential treatments for the novel coronavirus.
Business & Tech Gilead Sciences Stock Jumps After World Health Comments On Its Coronavirus Drug A World Health Organization official has said that Gilead's remdesivir is "the only drug right now that we think may have real efficacy" against the novel coronavirus that first appeared in China.
Business & Tech Bay Area-Based Gilead Sees Potential Legal Conflict With China Over Its Coronavirus Drug The Foster City-based pharmaceutical company Gilead Sciences, which specializes in antiviral drugs, recently donated some of its experimental drug remdesivir for use in studying potential treatments for the Wuhan coronavirus.
SF News PrEP-Maker Gilead Sued by Feds for Patent Infringement Foster City-based Gilead Sciences is accused is ripping off government patents to develop its blockbuster, billion-dollar HIV treatment PrEP.
